Abiraterone Acetate (CB 7630) is a highly active and selective 17α-hydroxylase/17,20 lyase (CYP17A1) inhibitor with an IC50 of 72 nM. Abiraterone Acetate (CB 7630) inhibitor CYP11B1, CYP11B2 and CYP3A4 with IC50 of 1.6, 1.8 and 2.7 μM. Abiraterone Acetate (CB 7630) is used in the study of castration-resistant prostate cancer. Abiraterone Acetate (CB 7630) blocks the formation of testosterone by inhibiting CYP17A1. Abiraterone Acetate (CB 7630) caused significant reductions in the weights of the ventral prostate and seminal vesicles. There was no reduction seen in the weight of these organs with KC. Abiraterone Acetate (CB 7630) reduced plasma testosterone to 0.1 nM or less, despite a three- to four-fold increase in the plasma level of luteinizing hormone (LH).
|Cell lines||LNCaP and VCaP cells|
|Preparation method||Seeding LNCaP and VCaP cells in 96-well plates and growing in CSS-supplemented phenol red-free or FBS-supplemented media for 7 days.Treatig cells with Abiraterone at 24 hours and 96 hours after plating and determining cell viability on day 7 by adding CellTiter Glo and measuring luminescence|
|Concentrations||0 μM -10 μM|
|Incubation time||24 hours and 96 hours|
|Animal models||Male NOD/SCID mice with LAPC4 cells|
|Formulation||0.1 mL 5% benzyl alcohol and 95% safflower oil solution|
|Administration||Administered via s.c.|
|Solubility (25°C)||Ethanol 20 mg/mL|
Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
 Daniel J Khalaf, et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial
 Karim Fizazi, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
 Karim Fizazi, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
 Karim Fizazi, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
|Related Cytochrome P450 (e.g. CYP17) Products|
HET0016 is a highly efficient and selective inhibitor of 20-HETE synthase, with IC50 values of 17.7 nM, 12.1 nM and 20.6 nM for recombinant CYP4A1, CYP4A2 and CYP4A3, respectively. HET0016 is a selective CYP450 inhibitor that has been shown to inhibit angiogenesis and tumor growth.
Soticlestat (TAK-935; OV935) is a first-in-class, potent, selective, orally active inhibitor of cholesterol 24-hydroxylase (CH24H), which is used in the study of epilepsy syndromes.
Pregnenolone 16α-carbonitrile is a derivative of pregnendione that functions as an agonist of the rodent pregnane X receptor (PXR). pregnenolone 16α-carbonitrile is a synthetic steroid that induces expression of cytochrome P450 3A. Pregnenolone 16α-carbonitrile exhibits greater tolerance to subsequent stress injury.
Oxolamine (SKF-9976, AF-438) citrate, a cough suppressant, is an inhibitor of CYP2B1/2. Oxolamine citrate also exhibits anti-inflammatory effect.
Ticlopidine (Yuclid, Ticlopidinum, Ticlopidina) is an orally active inhibitor of platelet aggregation induced by adenosine diphosphate (ADP). Ticlopidine is also an inhibitor of CYP2B6 with Ki of 0.2 μM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.